세포 및 유전자 치료 시장 규모와 예측(2021-2031년), 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 유형별, 서비스별, 규모별, 서비스 제공업체별, 트랜스펙션 시약별, 최종 사용자별, 지역별
Cell and Gene Therapy Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Service, Scale, Service Providers, Transfection Reagents, End User, and Geography
상품코드
:
1938233
리서치사
:
The Insight Partners
발행일
:
2026년 01월
페이지 정보
:
영문 300 Pages
영문 목차
The cell and gene therapy market size is expected to grow from US$ 5.30 billion in 2024 to US$ 25.78 billion by 2031; it is projected to register a CAGR of 25.5% during 2025-2031. The increasing prevalence of chronic and genetic diseases, the rapid popularity of outsourcing cell and gene therapy manufacturing, and surging regulatory approvals and commercialization are noteworthy factors contributing to the expansion of the cell and gene therapy market size. Additionally, the development of next-generation gene editing tools is projected to bring new cell and gene therapy market trends in the near future.
AI and automation are making a revolutionary impact in the realm of CGT. This academic field has been using AI for predictive modeling, in association with automated process improvement for planning, to overcome current challenges. CRISPR-GPT at Stanford Medicine, an AI technology capable of automating the planning of experiments related to editing genes, has reduced the "time burden of trial-and-error" phases from months to mere days. Similarly, the Yale School of Medicine's generative AI model designs "new DNA sequences" to switch genes "on" and "off" for the development of safer "gene therapy vectors" in preclinical studies.
Automation works well with AI as it reduces human involvement in the manufacturing process. In this regard, the Cell Shuttle system by Cellares relies on robotics for completeCAR-T cell manufacturing with higher purity and an increased processing speed of up to 10 times. These developments provide significant benefits. According to BioProcess International, automation can reduce autologous CGT cost by 30-50% through enhanced compliance and flexibility. The synergy between AI and automation fast-tracks CGT, which ensures equal treatment access for those affected by rising chronic diseases, thereby emerging as a significant trend in the cell and gene therapy market.
End User-Based Insights
Based on end user, the cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest cell and gene therapy market share in 2024. The driving forces of growth include increasing expenditures in the healthcare sector and favorable government regulations, which accelerate clinical trials; these offer attractions to MNCs looking for varying genetic backgrounds for the development of personalized medications. The growing number of genetic ailments as well as fewer costs of manufacturing act as stimuli for the domestic manufacturing of medications, thus facilitating a transition from generics to more advanced therapies like CAR-T. Improved regulatory harmonization among the countries, with Japan introducing conditional approval of regenerative therapies since 2014, reduces the risks associated with investment. Key players who have successfully developed CAR-T therapies in Japan include the country's own Astellas Pharma and Takeda Pharmaceutical companies, who have developed CAR-T candidates in Japan through clinical trials in patients with leukemia. Japan has the lead in adopting iPS cell technology through the Fujifilm Cellular Dynamics company. In China, Beigene and Legend Biotech (in collaboration with Johnson & Johnson) have commercialized BCMA-targeted therapies for multiple myeloma, benefiting from massive patient pools and government-backed bioclusters in Shanghai, thereby fueling the cell and gene therapy market growth.
The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the cell and gene therapy market report.
Table Of Contents
1. Executive Summary
- 1.1 Analyst Market Outlook
- 1.2 Market Attractiveness
2. Cell and Gene Therapy Market Landscape
- 2.1 Overview
- 2.2 Value Chain Analysis
- 2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
- 2.4 PEST Analysis
- 2.5 Impact of Artificial Intelligence (AI)
- 2.6 Cell Therapy or Technology Roadmap
- 2.7 Sustainability and ESG Trends
- 2.8 Patent Analysis
- 2.9 Regulatory Framework
3. Competitive Landscape
- 3.1 Company Benchmarking by Key Players
- 3.2 Market Share Analysis, 2024 - By Key Players
- 3.3 Market Concentration
4. Cell and Gene Therapy Market - Key Industry Dynamics
- 4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic and Genetic Diseases
- 4.1.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
- 4.1.3 Surging Regulatory Approvals and Commercialization
- 4.2 Market Restraints
- 4.2.1 High Costs of Development and Treatment
- 4.2.2 Stringent Regulatory Challenges
- 4.2.3 Shortage Of Skilled Professionals and Infrastructure
- 4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Companies
- 4.3.2 Supportive Government Initiatives
- 4.3.3 Rising Investments in Research & Development and Clinical Trials
- 4.4 Future Trends
- 4.4.1 Integration of AI and Automation
- 4.4.2 Development of Next-Generation Gene Editing Tools
- 4.4.3 Rise of Allogeneic and Off-The-Shelf Therapies
- 4.5 Impact of Drivers and Restraints
5. Cell and Gene Therapy Market - Global Market Analysis
- 5.1 Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
- 5.2 Cell and Gene Therapy Market Forecast and Analysis
6. Cell and Gene Therapy Market Revenue Analysis -Type
- 6.1 Cell and Gene Therapy Market Forecasts and Analysis by Type
- 6.1.1 Cell Therapy
- 6.1.1.1 Overview
- 6.1.1.2 Cell Therapy: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 6.1.2 Gene Therapy
- 6.1.2.1 Overview
- 6.1.2.2 Gene Therapy: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
7. Cell and Gene Therapy Market Revenue Analysis -Service
- 7.1 Cell and Gene Therapy Market Forecasts and Analysis by Service
- 7.1.1 Process Development
- 7.1.1.1 Overview
- 7.1.1.2 Process Development: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 7.1.2 cGMP Manufacturing
- 7.1.2.1 Overview
- 7.1.2.2 cGMP Manufacturing: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 7.1.3 Regulatory Services
- 7.1.3.1 Overview
- 7.1.3.2 Regulatory Services: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 7.1.4 Bioassay Services
- 7.1.4.1 Overview
- 7.1.4.2 Bioassay Services: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
8. Cell and Gene Therapy Market Revenue Analysis - Scale
- 8.1 Cell and Gene Therapy Market Forecasts and Analysis by Scale
- 8.1.1 Pre-commercial/R and D Manufacturing
- 8.1.1.1 Overview
- 8.1.1.2 Pre-commercial/R and D Manufacturing: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 8.1.2 Commercial Scale Manufacturing
- 8.1.2.1 Overview
- 8.1.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
9. Cell and Gene Therapy Market Revenue Analysis -Service Providers
- 9.1 Cell and Gene Therapy Market Forecasts and Analysis by Service Providers
- 9.1.1 CDMOs
- 9.1.1.1 Overview
- 9.1.1.2 CDMOs: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 9.1.2 CMOs
- 9.1.2.1 Overview
- 9.1.2.2 CMOs: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
10. Cell and Gene Therapy Market Revenue Analysis - Transfection Reagents
- 10.1 Cell and Gene Therapy Market Forecasts and Analysis by Transfection Reagents
- 10.1.1 Polymer-based Transfection Reagents
- 10.1.1.1 Overview
- 10.1.1.2 Polymer-based Transfection Reagents: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 10.1.2 Lipid-based Transfection Reagents
- 10.1.2.1 Overview
- 10.1.2.2 Lipid-based Transfection Reagents: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 10.1.3 Viral Transduction Enhancers
- 10.1.3.1 Overview
- 10.1.3.2 Viral Transduction Enhancers: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 10.1.4 Other Transfection Reagents
- 10.1.4.1 Overview
- 10.1.4.2 Other Transfection Reagents: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
11. Cell and Gene Therapy Market Revenue Analysis - By End User
- 11.1 Cell and Gene Therapy Market Forecasts and Analysis by End User
- 11.1.1 Contract Research Organizations
- 11.1.1.1 Overview
- 11.1.1.2 Contract Research Organizations: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 11.1.2 Pharmaceutical and Biopharmaceutical Companies
- 11.1.2.1 Overview
- 11.1.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
- 11.1. Academic and Research Institutes
- 11.1.3.1 Overview
- 11.1.3.2 Academic and Research Institutes: Cell and Gene Therapy Market -Revenue, 2021-2031 (US$ Million)
12. Cell and Gene Therapy Market - Geographical Analysis
- 12.1 North America
- 12.1.1 North America Cell and Gene Therapy Market Overview
- 12.1.2 North America: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.1.3 North America: Cell and Gene Therapy Market- By Segmentation
- 12.1.3.1 Type
- 12.1.3.2 Cell Therapy For Type
- 12.1.3.3 Gene Therapy For Type
- 12.1.3.4 Service
- 12.1.3.5 Scale
- 12.1.3.6 Service Providers
- 12.1.3.7 Transfection Reagents
- 12.1.3.8 End User
- 12.1.4 North America: Cell and Gene Therapy Market Breakdown by Countries
- 12.1.4.1 United States Market
- 12.1.4.1.1 United States: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.1.4.1.2 United States: Cell and Gene Therapy Market- By Segmentation
- 12.1.4.1.2.1 Type
- 12.1.4.1.2.2 Cell Therapy For Type
- 12.1.4.1.2.3 Gene Therapy For Type
- 12.1.4.1.2.4 Service
- 12.1.4.1.2.5 Scale
- 12.1.4.1.2.6 Service Providers
- 12.1.4.1.2.7 Transfection Reagents
- 12.1.4.1.2.8 End User
- 12.1.4.2 Canada Market
- 12.1.4.2.1 Canada: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.1.4.2.2 Canada: Cell and Gene Therapy Market- By Segmentation
- 12.1.4.2.2.1 Type
- 12.1.4.2.2.2 Cell Therapy For Type
- 12.1.4.2.2.3 Gene Therapy For Type
- 12.1.4.2.2.4 Service
- 12.1.4.2.2.5 Scale
- 12.1.4.2.2.6 Service Providers
- 12.1.4.2.2.7 Transfection Reagents
- 12.1.4.2.2.8 End User
- 12.1.4.3 Mexico Market
- 12.1.4.3.1 Mexico: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.1.4.3.2 Mexico: Cell and Gene Therapy Market- By Segmentation
- 12.1.4.3.2.1 Type
- 12.1.4.3.2.2 Cell Therapy For Type
- 12.1.4.3.2.3 Gene Therapy For Type
- 12.1.4.3.2.4 Service
- 12.1.4.3.2.5 Scale
- 12.1.4.3.2.6 Service Providers
- 12.1.4.3.2.7 Transfection Reagents
- 12.1.4.3.2.8 End User
- 12.2 Europe
- 12.2.1 Europe Cell and Gene Therapy Market Overview
- 12.2.2 Europe: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.3 Europe: Cell and Gene Therapy Market- By Segmentation
- 12.2.3.1 Type
- 12.2.3.2 Cell Therapy For Type
- 12.2.3.3 Gene Therapy For Type
- 12.2.3.4 Service
- 12.2.3.5 Scale
- 12.2.3.6 Service Providers
- 12.2.3.7 Transfection Reagents
- 12.2.3.8 End User
- 12.2.4 Europe: Cell and Gene Therapy Market Breakdown by Countries
- 12.2.4.1 United Kingdom Market
- 12.2.4.1.1 United Kingdom: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.1.2 United Kingdom: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.1.2.1 Type
- 12.2.4.1.2.2 Cell Therapy For Type
- 12.2.4.1.2.3 Gene Therapy For Type
- 12.2.4.1.2.4 Service
- 12.2.4.1.2.5 Scale
- 12.2.4.1.2.6 Service Providers
- 12.2.4.1.2.7 Transfection Reagents
- 12.2.4.1.2.8 End User
- 12.2.4.2 Germany Market
- 12.2.4.2.1 Germany: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.2.2 Germany: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.2.2.1 Type
- 12.2.4.2.2.2 Cell Therapy For Type
- 12.2.4.2.2.3 Gene Therapy For Type
- 12.2.4.2.2.4 Service
- 12.2.4.2.2.5 Scale
- 12.2.4.2.2.6 Service Providers
- 12.2.4.2.2.7 Transfection Reagents
- 12.2.4.2.2.8 End User
- 12.2.4.3 France Market
- 12.2.4.3.1 France: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.3.2 France: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.3.2.1 Type
- 12.2.4.3.2.2 Cell Therapy For Type
- 12.2.4.3.2.3 Gene Therapy For Type
- 12.2.4.3.2.4 Service
- 12.2.4.3.2.5 Scale
- 12.2.4.3.2.6 Service Providers
- 12.2.4.3.2.7 Transfection Reagents
- 12.2.4.3.2.8 End User
- 12.2.4.4 Italy Market
- 12.2.4.4.1 Italy: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.4.2 Italy: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.4.2.1 Type
- 12.2.4.4.2.2 Cell Therapy For Type
- 12.2.4.4.2.3 Gene Therapy For Type
- 12.2.4.4.2.4 Service
- 12.2.4.4.2.5 Scale
- 12.2.4.4.2.6 Service Providers
- 12.2.4.4.2.7 Transfection Reagents
- 12.2.4.4.2.8 End User
- 12.2.4.5 Spain Market
- 12.2.4.5.1 Spain: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.5.2 Spain: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.5.2.1 Type
- 12.2.4.5.2.2 Cell Therapy For Type
- 12.2.4.5.2.3 Gene Therapy For Type
- 12.2.4.5.2.4 Service
- 12.2.4.5.2.5 Scale
- 12.2.4.5.2.6 Service Providers
- 12.2.4.5.2.7 Transfection Reagents
- 12.2.4.5.2.8 End User
- 12.2.4.6 Rest of Europe Market
- 12.2.4.6.1 Rest of Europe: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.2.4.6.2 Rest of Europe: Cell and Gene Therapy Market- By Segmentation
- 12.2.4.6.2.1 Type
- 12.2.4.6.2.2 Cell Therapy For Type
- 12.2.4.6.2.3 Gene Therapy For Type
- 12.2.4.6.2.4 Service
- 12.2.4.6.2.5 Scale
- 12.2.4.6.2.6 Service Providers
- 12.2.4.6.2.7 Transfection Reagents
- 12.2.4.6.2.8 End User
- 12.3 Asia Pacific
- 12.3.1 Asia Pacific Cell and Gene Therapy Market Overview
- 12.3.2 Asia Pacific: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.3 Asia Pacific: Cell and Gene Therapy Market- By Segmentation
- 12.3.3.1 Type
- 12.3.3.2 Cell Therapy For Type
- 12.3.3.3 Gene Therapy For Type
- 12.3.3.4 Service
- 12.3.3.5 Scale
- 12.3.3.6 Service Providers
- 12.3.3.7 Transfection Reagents
- 12.3.3.8 End User
- 12.3.4 Asia Pacific: Cell and Gene Therapy Market Breakdown by Countries
- 12.3.4.1 China Market
- 12.3.4.1.1 China: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.1.2 China: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.1.2.1 Type
- 12.3.4.1.2.2 Cell Therapy For Type
- 12.3.4.1.2.3 Gene Therapy For Type
- 12.3.4.1.2.4 Service
- 12.3.4.1.2.5 Scale
- 12.3.4.1.2.6 Service Providers
- 12.3.4.1.2.7 Transfection Reagents
- 12.3.4.1.2.8 End User
- 12.3.4.2 Japan Market
- 12.3.4.2.1 Japan: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.2.2 Japan: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.2.2.1 Type
- 12.3.4.2.2.2 Cell Therapy For Type
- 12.3.4.2.2.3 Gene Therapy For Type
- 12.3.4.2.2.4 Service
- 12.3.4.2.2.5 Scale
- 12.3.4.2.2.6 Service Providers
- 12.3.4.2.2.7 Transfection Reagents
- 12.3.4.2.2.8 End User
- 12.3.4.3 India Market
- 12.3.4.3.1 India: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.3.2 India: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.3.2.1 Type
- 12.3.4.3.2.2 Cell Therapy For Type
- 12.3.4.3.2.3 Gene Therapy For Type
- 12.3.4.3.2.4 Service
- 12.3.4.3.2.5 Scale
- 12.3.4.3.2.6 Service Providers
- 12.3.4.3.2.7 Transfection Reagents
- 12.3.4.3.2.8 End User
- 12.3.4.4 Australia Market
- 12.3.4.4.1 Australia: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.4.2 Australia: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.4.2.1 Type
- 12.3.4.4.2.2 Cell Therapy For Type
- 12.3.4.4.2.3 Gene Therapy For Type
- 12.3.4.4.2.4 Service
- 12.3.4.4.2.5 Scale
- 12.3.4.4.2.6 Service Providers
- 12.3.4.4.2.7 Transfection Reagents
- 12.3.4.4.2.8 End User
- 12.3.4.5 South Korea Market
- 12.3.4.5.1 South Korea: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.5.2 South Korea: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.5.2.1 Type
- 12.3.4.5.2.2 Cell Therapy For Type
- 12.3.4.5.2.3 Gene Therapy For Type
- 12.3.4.5.2.4 Service
- 12.3.4.5.2.5 Scale
- 12.3.4.5.2.6 Service Providers
- 12.3.4.5.2.7 Transfection Reagents
- 12.3.4.5.2.8 End User
- 12.3.4.6 Rest of APAC Market
- 12.3.4.6.1 Rest of APAC: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.3.4.6.2 Rest of APAC: Cell and Gene Therapy Market- By Segmentation
- 12.3.4.6.2.1 Type
- 12.3.4.6.2.2 Cell Therapy For Type
- 12.3.4.6.2.3 Gene Therapy For Type
- 12.3.4.6.2.4 Service
- 12.3.4.6.2.5 Scale
- 12.3.4.6.2.6 Service Providers
- 12.3.4.6.2.7 Transfection Reagents
- 12.3.4.6.2.8 End User
- 12.4 Middle East and Africa
- 12.4.1 Middle East and Africa Cell and Gene Therapy Market Overview
- 12.4.2 Middle East and Africa: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.4.3 Middle East and Africa: Cell and Gene Therapy Market- By Segmentation
- 12.4.3.1 Type
- 12.4.3.2 Cell Therapy For Type
- 12.4.3.3 Gene Therapy For Type
- 12.4.3.4 Service
- 12.4.3.5 Scale
- 12.4.3.6 Service Providers
- 12.4.3.7 Transfection Reagents
- 12.4.3.8 End User
- 12.4.4 Middle East and Africa: Cell and Gene Therapy Market Breakdown by Countries
- 12.4.4.1 Saudi Arabia Market
- 12.4.4.1.1 Saudi Arabia: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.4.4.1.2 Saudi Arabia: Cell and Gene Therapy Market- By Segmentation
- 12.4.4.1.2.1 Type
- 12.4.4.1.2.2 Cell Therapy For Type
- 12.4.4.1.2.3 Gene Therapy For Type
- 12.4.4.1.2.4 Service
- 12.4.4.1.2.5 Scale
- 12.4.4.1.2.6 Service Providers
- 12.4.4.1.2.7 Transfection Reagents
- 12.4.4.1.2.8 End User
- 12.4.4.2 South Africa Market
- 12.4.4.2.1 South Africa: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.4.4.2.2 South Africa: Cell and Gene Therapy Market- By Segmentation
- 12.4.4.2.2.1 Type
- 12.4.4.2.2.2 Cell Therapy For Type
- 12.4.4.2.2.3 Gene Therapy For Type
- 12.4.4.2.2.4 Service
- 12.4.4.2.2.5 Scale
- 12.4.4.2.2.6 Service Providers
- 12.4.4.2.2.7 Transfection Reagents
- 12.4.4.2.2.8 End User
- 12.4.4.3 United Arab Emirates Market
- 12.4.4.3.1 United Arab Emirates: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.4.4.3.2 United Arab Emirates: Cell and Gene Therapy Market- By Segmentation
- 12.4.4.3.2.1 Type
- 12.4.4.3.2.2 Cell Therapy For Type
- 12.4.4.3.2.3 Gene Therapy For Type
- 12.4.4.3.2.4 Service
- 12.4.4.3.2.5 Scale
- 12.4.4.3.2.6 Service Providers
- 12.4.4.3.2.7 Transfection Reagents
- 12.4.4.3.2.8 End User
- 12.4.4.4 Rest of Middle East and Africa Market
- 12.4.4.4.1 Rest of Middle East and Africa: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.4.4.4.2 Rest of Middle East and Africa: Cell and Gene Therapy Market- By Segmentation
- 12.4.4.4.2.1 Type
- 12.4.4.4.2.2 Cell Therapy For Type
- 12.4.4.4.2.3 Gene Therapy For Type
- 12.4.4.4.2.4 Service
- 12.4.4.4.2.5 Scale
- 12.4.4.4.2.6 Service Providers
- 12.4.4.4.2.7 Transfection Reagents
- 12.4.4.4.2.8 End User
- 12.5 South and Central America
- 12.5.1 South and Central America Cell and Gene Therapy Market Overview
- 12.5.2 South and Central America: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.5.3 South and Central America: Cell and Gene Therapy Market- By Segmentation
- 12.5.3.1 Type
- 12.5.3.2 Cell Therapy For Type
- 12.5.3.3 Gene Therapy For Type
- 12.5.3.4 Service
- 12.5.3.5 Scale
- 12.5.3.6 Service Providers
- 12.5.3.7 Transfection Reagents
- 12.5.3.8 End User
- 12.5.4 South and Central America: Cell and Gene Therapy Market Breakdown by Countries
- 12.5.4.1 Brazil Market
- 12.5.4.1.1 Brazil: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.5.4.1.2 Brazil: Cell and Gene Therapy Market- By Segmentation
- 12.5.4.1.2.1 Type
- 12.5.4.1.2.2 Cell Therapy For Type
- 12.5.4.1.2.3 Gene Therapy For Type
- 12.5.4.1.2.4 Service
- 12.5.4.1.2.5 Scale
- 12.5.4.1.2.6 Service Providers
- 12.5.4.1.2.7 Transfection Reagents
- 12.5.4.1.2.8 End User
- 12.5.4.2 Argentina Market
- 12.5.4.2.1 Argentina: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.5.4.2.2 Argentina: Cell and Gene Therapy Market- By Segmentation
- 12.5.4.2.2.1 Type
- 12.5.4.2.2.2 Cell Therapy For Type
- 12.5.4.2.2.3 Gene Therapy For Type
- 12.5.4.2.2.4 Service
- 12.5.4.2.2.5 Scale
- 12.5.4.2.2.6 Service Providers
- 12.5.4.2.2.7 Transfection Reagents
- 12.5.4.2.2.8 End User
- 12.5.4.3 Rest of South and Central America Market
- 12.5.4.3.1 Rest of South and Central America: Cell and Gene Therapy Market Revenue and Forecasts, 2021-2031 (US$ Million)
- 12.5.4.3.2 Rest of South and Central America: Cell and Gene Therapy Market- By Segmentation
- 12.5.4.3.2.1 Type
- 12.5.4.3.2.2 Cell Therapy For Type
- 12.5.4.3.2.3 Gene Therapy For Type
- 12.5.4.3.2.4 Service
- 12.5.4.3.2.5 Scale
- 12.5.4.3.2.6 Service Providers
- 12.5.4.3.2.7 Transfection Reagents
- 12.5.4.3.2.8 End User
13. Cell and Gene Therapy Market Industry Landscape
14. Cell and Gene Therapy Market - Key Company Profiles
- 14.1 CRISPR Therapeutics
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Cell Therapys and Gene Therapy
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Horizon Discovery Group plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Cell Therapys and Gene Therapy
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Thermo Fisher Scientific Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Cell Therapys and Gene Therapy
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 Merck KGaA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Cell Therapys and Gene Therapy
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Integrated DNA Technologies Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Cell Therapys and Gene Therapy
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 QIAGEN NV
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Cell Therapys and Gene Therapy
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 Takara Bio Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Cell Therapys and Gene Therapy
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Synthego Holdings LLC
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Cell Therapys and Gene Therapy
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 GenScript Biotech Corporation
- 14.9.1 Key Facts
- 14.12.2 Business Description
- 14.12.3 Cell Therapys and Gene Therapy
- 14.12.4 Financial Overview
- 14.12.5 SWOT Analysis
- 14.9.6 Key Developments
- 14.10 Editas Medicine Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Cell Therapys and Gene Therapy
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
- 15.1 Glossary
- 15.2 Research Methodology and Approach
- 15.2.1 Secondary Research
- 15.2.2 Primary Research
- 15.2.3 Market Estimation Approach
- 15.2.3.1 Supply Side Analysis
- 15.2.3.2 Demand Side Analysis
- 15.2.4 Research Assumptions and Limitations
- 15.2.5 Currency Conversion
- 15.3 About The Insight Partners
- 15.4 Market Intelligence Cloud
관련자료
